Overview
Polycythemia vera is a chronic blood cancer of the myeloproliferative neoplasm family in which the bone marrow overproduces red blood cells, and often white blood cells and platelets as well. The excess red cells thicken the blood, raising the risk of clotting, stroke, heart attack, and other vascular complications, and can cause symptoms such as headache, dizziness, itching, and an enlarged spleen. The disease is driven in the great majority of cases by an acquired mutation in the JAK2 gene, which causes blood-forming cells to proliferate independently of normal regulatory signals. Diagnosis relies on blood counts, JAK2 mutation testing, and bone marrow assessment, while management aims to reduce blood thickness and clotting risk through measures such as phlebotomy, low-dose aspirin, and cytoreductive drugs including hydroxyurea. Research relevant to this topic in Hematology and Oncology Research includes a case report of unusual cutaneous toxicity following prolonged hydroxyurea use in polycythemia vera, and a report describing the evolution of JAK2 V617F-negative idiopathic myelofibrosis into Philadelphia-positive chronic myeloid leukemia, both reflecting the journal's coverage of myeloproliferative disorders and their treatment. This page gathers peer-reviewed, open-access research relevant to polycythemia vera and related blood disorders.
Research published in this journal
2 peer-reviewed articles, ranked by relevance. Each links to its DOI.
Evolution of Janus Kinase 2 V617F-negative idiopathic myelofibrosis into Philadelphia+ chronic myeloid leukemia
How this research is being cited
The 2 articles above have been cited 1 time in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2015 · Journal of Hematology and Oncology Research
A sample of recent works citing this journal's research on Polycythemia Vera, linking to each citing work.